A positive role for Runx1 was also suggested by its upregulation in hearts treated with oncostatin M, which has been shown to protect the heart after acute myocardial infarction (Kubin et al., 2011), as well as in hearts that overexpress Erbb2 and show enhanced myocardial proliferation and regeneration (D'Uva et al., 2015). Here, ERBB2 is linked to myocardial infarction.